Paper Details

  1. Home
  2. Paper Details

Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib.

Author: AtesOzturk, BuyukkorMustafa, TayFatih

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case report describes two patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung adenocarcinoma (NSCLC) who were infected with COVID-19 and treated with favipiravir. The patients had previously received multi-line therapy with brigatinib and lorlatinib. This report highlights the challenges of managing COVID-19 in patients with ALK+ NSCLC who have received multiple lines of therapy.
Paper Details　
Original Abstract of the Article :
The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552221083321

データ提供：米国国立医学図書館（NLM）

Favipiravir in Combination Therapy for ALK+ NSCLC Patients with COVID-19

This research examines the [use of Favipiravir in combination therapy] for [ALK+ non-small cell lung adenocarcinoma (NSCLC) patients] who are also [infected with COVID-19]. The study presents two [case studies] highlighting the [clinical management] of these patients, who had previously received [Brigatinib and Lorlatinib]. The findings underscore the [challenges of managing cancer patients during the COVID-19 pandemic] and highlight the [potential role of Favipiravir] in [treating COVID-19 in this specific patient population].

A Balancing Act: Managing Cancer and COVID-19 in Complex Cases

The study emphasizes the [importance of individualized treatment plans] for [patients with complex conditions], such as [ALK+ NSCLC] and [COVID-19]. The findings highlight the [need for careful monitoring and adjustments] in [medication regimens] to [optimize patient outcomes] and [manage potential drug interactions].

Navigating the Storm of COVID-19: Finding Solutions for Cancer Patients

The COVID-19 pandemic has posed significant challenges for [cancer patients], who are often [immunocompromised] and at [increased risk of complications]. This study underscores the [need for innovative treatment approaches] and [collaborative efforts] to [improve the care and outcomes] for these individuals.

Dr. Camel's Conclusion

Just as a camel navigates a sandstorm, relying on its instincts and experience, healthcare professionals need to navigate the challenges of COVID-19 in cancer patients, finding solutions that balance the need for effective cancer treatment with the management of viral infection. This study highlights the importance of personalized care and ongoing research in addressing this complex issue.
Date :
  1. Date Completed 2022-11-01
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

35225067

DOI: Digital Object Identifier

10.1177/10781552221083321

Related Literature

Article Analysis
・Side Effects of lorlatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.